In this review:
MRI shows early effects of tocilizumab
Tocilizumab in previous DMARD- and TNF-failure patients
Tocilizumab in systemic juvenile idiopathic arthritis
Rituximab inhibits joint damage
Higher rituximab dose achieves clinical response
Rituximab treat to target
Please login below to download this issue (PDF)